TSS
GNMX

Two Sigma Securities’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Two Sigma Securities’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-38,726
Closed -$6K – 2624
2019
Q2 		$6K Buy
+38,726
New +$7.84K ﹤0.01% 2025
2018
Q4 		– Sell
-14,138
Closed -$17K – 3074
2018
Q3 		$17K Buy
+14,138
New +$15.8K ﹤0.01% 2464

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's GNMX Position: Q3 2019 in Review

Two Sigma Securities sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2019, closing a stake of 38,726 shares — an estimated $6K sold.

Two Sigma Securities first reported a position in GNMX in Q3 2018 and held it in 2 quarters. The position peaked at $17K in Q3 2018. 25 funds tracked by Wall St. Rank hold GNMX as of Q3 2019.

  • Two Sigma Securities reported no remaining Aevi Genomic Medicine Inc position as of Q3 2019 after selling out during the quarter.
  • Two Sigma Securities sold 38,726 Aevi Genomic Medicine Inc shares in Q3 2019, an estimated $6K.
  • Two Sigma Securities first reported a position in Aevi Genomic Medicine Inc in Q3 2018 and held it in 2 quarters.
  • Two Sigma Securities's Aevi Genomic Medicine Inc position peaked at $17K in Q3 2018.
  • 25 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2019.

Based on Two Sigma Securities's 13F filing for Q3 2019, filed 14 Nov 2019.